{
  "metadata": {
    "competency_question": "What known genes or pathways are implicated in minimizing Doxorubicin toxicity while preserving its anti-tumor efficacy for NF1?",
    "protocol": "Fuzzy-to-Fact v4",
    "timestamp": "2026-02-20",
    "phases_completed": ["ANCHOR", "ENRICH", "EXPAND", "TRAVERSE_DRUGS", "TRAVERSE_TRIALS", "VALIDATE", "PERSIST"]
  },
  "nodes": [
    {
      "id": "HGNC:7765",
      "type": "Gene",
      "label": "NF1",
      "properties": {
        "symbol": "NF1",
        "name": "neurofibromin 1",
        "ensembl": "ENSG00000196712",
        "uniprot": "P21359",
        "entrez": "4763",
        "location": "17q11.2",
        "function": "Stimulates the GTPase activity of Ras. NF1 shows greater affinity for Ras GAP, but lower specific activity. May be a regulator of Ras activity",
        "role_in_question": "Primary disease gene. NF1 loss activates RAS/MAPK signaling, driving NF1-associated tumors (MPNSTs, neurofibromas). Doxorubicin is used for NF1-associated malignancies.",
        "source": "hgnc_get_gene(HGNC:7765), uniprot_get_protein(UniProtKB:P21359)"
      }
    },
    {
      "id": "HGNC:11989",
      "type": "Gene",
      "label": "TOP2A",
      "properties": {
        "symbol": "TOP2A",
        "name": "DNA topoisomerase II alpha",
        "ensembl": "ENSG00000131747",
        "uniprot": "P11388",
        "entrez": "7153",
        "location": "17q21.2",
        "function": "Key decatenating enzyme that alters DNA topology by binding to two double-stranded DNA molecules, generating a double-stranded break in one of the strands, passing the intact strand through the broken strand, and religating the broken strand",
        "role_in_question": "PRIMARY therapeutic target of doxorubicin. Inhibition of TOP2A mediates anti-tumor efficacy. Preserving TOP2A inhibition is essential for anti-tumor activity.",
        "source": "hgnc_get_gene(HGNC:11989), uniprot_get_protein(UniProtKB:P11388), Open Targets GraphQL drug(CHEMBL53463).mechanismsOfAction"
      }
    },
    {
      "id": "HGNC:11990",
      "type": "Gene",
      "label": "TOP2B",
      "properties": {
        "symbol": "TOP2B",
        "name": "DNA topoisomerase II beta",
        "ensembl": "ENSG00000077097",
        "uniprot": "Q02880",
        "entrez": "7155",
        "location": "3p24.2",
        "function": "Key decatenating enzyme that alters DNA topology. Plays a role in B-cell differentiation",
        "role_in_question": "CRITICAL toxicity mediator. TOP2B is implicated in doxorubicin-induced cardiotoxicity. Dexrazoxane targets TOP2B to provide cardioprotection. Selectively sparing TOP2B while maintaining TOP2A inhibition is the key strategy for toxicity minimization.",
        "source": "hgnc_get_gene(HGNC:11990), uniprot_get_protein(UniProtKB:Q02880), Open Targets GraphQL drug(CHEMBL1738).mechanismsOfAction"
      }
    },
    {
      "id": "HGNC:6407",
      "type": "Gene",
      "label": "KRAS",
      "properties": {
        "symbol": "KRAS",
        "name": "KRAS proto-oncogene, GTPase",
        "ensembl": "ENSG00000133703",
        "uniprot": "P01116",
        "entrez": "3845",
        "location": "12p12.1",
        "role_in_question": "Direct signaling partner of NF1. NF1 loss leads to constitutive KRAS activation, driving RAS/MAPK signaling and tumorigenesis in NF1 patients.",
        "source": "hgnc_get_gene(HGNC:6407), string_get_interactions(NF1, score=0.996)"
      }
    },
    {
      "id": "HGNC:7782",
      "type": "Gene",
      "label": "NFE2L2",
      "properties": {
        "symbol": "NFE2L2",
        "name": "NFE2 like bZIP transcription factor 2",
        "ensembl": "ENSG00000116044",
        "uniprot": "Q16236",
        "entrez": "4780",
        "location": "2q31.2",
        "alias": "NRF2",
        "role_in_question": "Master transcription factor for oxidative stress response. Key regulator of antioxidant genes (SOD2, HMOX1, NQO1, CAT, GPX1). NFE2L2/NRF2 pathway activation is a primary defense mechanism against doxorubicin-induced oxidative damage.",
        "source": "hgnc_get_gene(HGNC:7782), wikipathways_get_pathway_components(WP:WP408), wikipathways_get_pathways_for_gene(NFE2L2)"
      }
    },
    {
      "id": "HGNC:11180",
      "type": "Gene",
      "label": "SOD2",
      "properties": {
        "symbol": "SOD2",
        "name": "superoxide dismutase 2",
        "ensembl": "ENSG00000291237",
        "uniprot": "P04179",
        "entrez": "6648",
        "location": "6q25.3",
        "alias": "MnSOD",
        "role_in_question": "Mitochondrial superoxide dismutase. Neutralizes superoxide radicals generated by doxorubicin redox cycling. Member of oxidative stress response pathway (WP408).",
        "source": "hgnc_get_gene(HGNC:11180), wikipathways_get_pathway_components(WP:WP408)"
      }
    },
    {
      "id": "HGNC:5013",
      "type": "Gene",
      "label": "HMOX1",
      "properties": {
        "symbol": "HMOX1",
        "name": "heme oxygenase 1",
        "ensembl": "ENSG00000100292",
        "uniprot": "P09601",
        "entrez": "3162",
        "location": "22q12.3",
        "alias": "HO-1",
        "role_in_question": "Cytoprotective enzyme regulated by NFE2L2. Degrades heme to biliverdin (antioxidant), carbon monoxide (anti-inflammatory), and free iron. Member of oxidative stress response pathway (WP408).",
        "source": "hgnc_get_gene(HGNC:5013), wikipathways_get_pathway_components(WP:WP408)"
      }
    },
    {
      "id": "HGNC:2874",
      "type": "Gene",
      "label": "NQO1",
      "properties": {
        "symbol": "NQO1",
        "name": "NAD(P)H quinone dehydrogenase 1",
        "ensembl": "ENSG00000181019",
        "uniprot": "P15559",
        "entrez": "1728",
        "location": "16q22.1",
        "alias": "DT-diaphorase",
        "role_in_question": "Two-electron reductase that detoxifies quinones by bypassing semiquinone radical intermediate. Directly relevant to doxorubicin (an anthraquinone). Member of oxidative stress response pathway (WP408).",
        "source": "hgnc_get_gene(HGNC:2874), wikipathways_get_pathway_components(WP:WP408)"
      }
    },
    {
      "id": "HGNC:1516",
      "type": "Gene",
      "label": "CAT",
      "properties": {
        "symbol": "CAT",
        "name": "catalase",
        "ensembl": "ENSG00000121691",
        "uniprot": "P04040",
        "entrez": "847",
        "location": "11p13",
        "role_in_question": "Decomposes hydrogen peroxide to water and oxygen. Protects cells from doxorubicin-generated H2O2. Member of oxidative stress response pathway (WP408).",
        "source": "hgnc_get_gene(HGNC:1516), wikipathways_get_pathway_components(WP:WP408)"
      }
    },
    {
      "id": "HGNC:4553",
      "type": "Gene",
      "label": "GPX1",
      "properties": {
        "symbol": "GPX1",
        "name": "glutathione peroxidase 1",
        "ensembl": "ENSG00000233276",
        "uniprot": "P07203",
        "entrez": "2876",
        "location": "3p21.31",
        "role_in_question": "Reduces hydrogen peroxide and organic hydroperoxides using glutathione. Protects against doxorubicin-induced oxidative damage. Member of oxidative stress response pathway (WP408).",
        "source": "hgnc_get_gene(HGNC:4553), wikipathways_get_pathway_components(WP:WP408)"
      }
    },
    {
      "id": "HGNC:40",
      "type": "Gene",
      "label": "ABCB1",
      "properties": {
        "symbol": "ABCB1",
        "name": "ATP binding cassette subfamily B member 1",
        "ensembl": "ENSG00000085563",
        "uniprot": "P08183",
        "entrez": "5243",
        "location": "7q21.12",
        "alias": "MDR1, P-glycoprotein",
        "role_in_question": "Drug efflux transporter. Pumps doxorubicin out of cells. Relevant to both drug resistance (tumor) and toxicity (normal tissue protection). Overexpression in cardiac tissue could reduce cardiotoxicity but may also reduce anti-tumor efficacy if expressed in tumors.",
        "source": "hgnc_get_gene(HGNC:40)"
      }
    },
    {
      "id": "HGNC:9866",
      "type": "Gene",
      "label": "RARG",
      "properties": {
        "symbol": "RARG",
        "name": "retinoic acid receptor gamma",
        "ensembl": "ENSG00000172819",
        "uniprot": "P13631",
        "entrez": "5916",
        "location": "12q13.13",
        "role_in_question": "Nuclear receptor implicated in doxorubicin cardiotoxicity susceptibility. Genetic variants near RARG have been identified in pharmacogenomic studies of anthracycline cardiotoxicity.",
        "source": "hgnc_get_gene(HGNC:9866), opentargets_get_associations(ENSG00000172819)"
      }
    },
    {
      "id": "HGNC:1548",
      "type": "Gene",
      "label": "CBR1",
      "properties": {
        "symbol": "CBR1",
        "name": "carbonyl reductase 1",
        "ensembl": "ENSG00000159228",
        "uniprot": "P16152",
        "entrez": "873",
        "location": "21q22.12",
        "role_in_question": "Metabolizes doxorubicin to doxorubicinol (cardiotoxic metabolite). Inhibition of CBR1 may reduce cardiotoxicity by decreasing doxorubicinol formation.",
        "source": "hgnc_get_gene(HGNC:1548)"
      }
    },
    {
      "id": "HGNC:1549",
      "type": "Gene",
      "label": "CBR3",
      "properties": {
        "symbol": "CBR3",
        "name": "carbonyl reductase 3",
        "ensembl": "ENSG00000159231",
        "uniprot": "O75828",
        "entrez": "874",
        "location": "21q22.12",
        "role_in_question": "Second carbonyl reductase that metabolizes doxorubicin to doxorubicinol. Genetic variants (e.g., CBR3 V244M) affect doxorubicin metabolism rates and cardiotoxicity risk.",
        "source": "hgnc_get_gene(HGNC:1549)"
      }
    },
    {
      "id": "HGNC:16484",
      "type": "Gene",
      "label": "SLC28A3",
      "properties": {
        "symbol": "SLC28A3",
        "name": "solute carrier family 28 member 3",
        "ensembl": "ENSG00000197506",
        "uniprot": "Q9HAS3",
        "entrez": "64078",
        "location": "9q21.32-q21.33",
        "alias": "CNT3",
        "role_in_question": "Concentrative nucleoside transporter. Variants in SLC28A3 have been associated with anthracycline-induced cardiotoxicity risk in pharmacogenomic studies.",
        "source": "hgnc_get_gene(HGNC:16484)"
      }
    },
    {
      "id": "CHEMBL:53463",
      "type": "Compound",
      "label": "Doxorubicin",
      "properties": {
        "chembl_id": "CHEMBL:53463",
        "pubchem_cid": "PubChem:CID31703",
        "mechanism": "DNA topoisomerase II alpha inhibitor",
        "max_phase": 4,
        "molecular_formula": "C27H29NO11",
        "molecular_weight": 543.53,
        "synonyms": ["Adriamycin", "Hydroxydaunorubicin"],
        "source": "chembl_get_compound(CHEMBL:53463), pubchem_get_compound(PubChem:CID31703), Open Targets GraphQL"
      }
    },
    {
      "id": "CHEMBL:1738",
      "type": "Compound",
      "label": "Dexrazoxane",
      "properties": {
        "chembl_id": "CHEMBL:1738",
        "mechanism": "DNA topoisomerase II inhibitor (cardioprotectant)",
        "max_phase": 4,
        "role_in_question": "FDA-approved cardioprotectant used with doxorubicin. Inhibits both TOP2A and TOP2B. Prevents doxorubicin-induced cardiotoxicity.",
        "source": "chembl_search_compounds(dexrazoxane), Open Targets GraphQL drug(CHEMBL1738).mechanismsOfAction"
      }
    },
    {
      "id": "MONDO:0018975",
      "type": "Disease",
      "label": "neurofibromatosis type 1",
      "properties": {
        "source": "opentargets_get_associations(ENSG00000196712), score=0.885"
      }
    },
    {
      "id": "WP:WP408",
      "type": "Pathway",
      "label": "Oxidative stress response",
      "properties": {
        "organism": "Homo sapiens",
        "role_in_question": "Central pathway for defense against doxorubicin-generated ROS. Contains NFE2L2 (master regulator), SOD2, CAT, GPX1, HMOX1, NQO1, GSR, GCLC, TXNRD1/2.",
        "source": "wikipathways_search_pathways(oxidative stress), wikipathways_get_pathway_components(WP:WP408)"
      }
    },
    {
      "id": "WP:WP2884",
      "type": "Pathway",
      "label": "NRF2 pathway",
      "properties": {
        "organism": "Homo sapiens",
        "role_in_question": "NRF2-specific signaling pathway. NFE2L2 activates transcription of cytoprotective genes in response to oxidative stress.",
        "source": "wikipathways_get_pathways_for_gene(NFE2L2)"
      }
    },
    {
      "id": "WP:WP4357",
      "type": "Pathway",
      "label": "NRF2-ARE regulation",
      "properties": {
        "organism": "Homo sapiens",
        "role_in_question": "Antioxidant Response Element (ARE) regulation by NRF2. Controls expression of phase II detoxification enzymes.",
        "source": "wikipathways_get_pathways_for_gene(NFE2L2)"
      }
    },
    {
      "id": "WP:WP2735",
      "type": "Pathway",
      "label": "RAF/MAP kinase cascade",
      "properties": {
        "organism": "Homo sapiens",
        "role_in_question": "Core signaling cascade downstream of NF1/RAS. NF1 loss deregulates this pathway, driving tumorigenesis.",
        "source": "wikipathways_get_pathways_for_gene(NF1)"
      }
    },
    {
      "id": "WP:WP4223",
      "type": "Pathway",
      "label": "Ras signaling",
      "properties": {
        "organism": "Homo sapiens",
        "role_in_question": "NF1 is a key negative regulator of Ras signaling. NF1 loss leads to constitutive Ras activation.",
        "source": "wikipathways_get_pathways_for_gene(NF1)"
      }
    },
    {
      "id": "NCT:00304083",
      "type": "ClinicalTrial",
      "label": "Phase II Chemotherapy in NF1-Associated MPNSTs",
      "properties": {
        "title": "Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors",
        "status": "COMPLETED",
        "interventions": ["doxorubicin hydrochloride", "etoposide", "ifosfamide"],
        "conditions": ["Neurofibromatosis Type 1", "Sarcoma"],
        "sponsors": ["Sarcoma Alliance for Research through Collaboration", "NCI"],
        "validation_status": "VALIDATED",
        "source": "clinicaltrials_search_trials(doxorubicin neurofibromatosis), clinicaltrials_get_trial(NCT:00304083)"
      }
    },
    {
      "id": "NCT:06220032",
      "type": "ClinicalTrial",
      "label": "ANTICIPATE: Dexrazoxane Cardioprotection Trial",
      "properties": {
        "title": "ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane",
        "status": "RECRUITING",
        "interventions": ["Dexrazoxane", "Doxorubicin", "Rituximab", "Cyclophosphamide", "Vincristine"],
        "conditions": ["DLBCL - Diffuse Large B Cell Lymphoma"],
        "sponsors": ["Stichting Hemato-Oncologie voor Volwassenen Nederland"],
        "start_date": "2024-08-15",
        "validation_status": "VALIDATED",
        "source": "clinicaltrials_search_trials(doxorubicin cardiotoxicity dexrazoxane), clinicaltrials_get_trial(NCT:06220032)"
      }
    }
  ],
  "edges": [
    {
      "source": "CHEMBL:53463",
      "target": "HGNC:11989",
      "type": "INHIBITOR",
      "properties": {
        "mechanism": "DNA topoisomerase II alpha inhibitor",
        "context": "Primary anti-tumor mechanism of doxorubicin",
        "source": "Open Targets GraphQL drug(CHEMBL53463).mechanismsOfAction"
      }
    },
    {
      "source": "CHEMBL:1738",
      "target": "HGNC:11989",
      "type": "INHIBITOR",
      "properties": {
        "mechanism": "DNA topoisomerase II inhibitor",
        "source": "Open Targets GraphQL drug(CHEMBL1738).mechanismsOfAction"
      }
    },
    {
      "source": "CHEMBL:1738",
      "target": "HGNC:11990",
      "type": "INHIBITOR",
      "properties": {
        "mechanism": "DNA topoisomerase II inhibitor",
        "context": "Cardioprotective mechanism - prevents doxorubicin-TOP2B-mediated cardiotoxicity",
        "source": "Open Targets GraphQL drug(CHEMBL1738).mechanismsOfAction"
      }
    },
    {
      "source": "HGNC:7765",
      "target": "HGNC:6407",
      "type": "REGULATES",
      "properties": {
        "direction": "repression",
        "mechanism": "NF1 (neurofibromin) stimulates GTPase activity of KRAS, converting active KRAS-GTP to inactive KRAS-GDP",
        "string_score": 0.996,
        "source": "string_get_interactions(NF1), uniprot_get_protein(UniProtKB:P21359)"
      }
    },
    {
      "source": "HGNC:7765",
      "target": "MONDO:0018975",
      "type": "ASSOCIATED_WITH",
      "properties": {
        "score": 0.885,
        "source": "opentargets_get_associations(ENSG00000196712)"
      }
    },
    {
      "source": "HGNC:7782",
      "target": "HGNC:11180",
      "type": "REGULATES",
      "properties": {
        "direction": "activation",
        "mechanism": "NFE2L2 (NRF2) transcriptionally activates SOD2 via antioxidant response element",
        "source": "wikipathways_get_pathway_components(WP:WP408)"
      }
    },
    {
      "source": "HGNC:7782",
      "target": "HGNC:5013",
      "type": "REGULATES",
      "properties": {
        "direction": "activation",
        "mechanism": "NFE2L2 (NRF2) transcriptionally activates HMOX1",
        "source": "wikipathways_get_pathway_components(WP:WP408)"
      }
    },
    {
      "source": "HGNC:7782",
      "target": "HGNC:2874",
      "type": "REGULATES",
      "properties": {
        "direction": "activation",
        "mechanism": "NFE2L2 (NRF2) transcriptionally activates NQO1",
        "source": "wikipathways_get_pathway_components(WP:WP408)"
      }
    },
    {
      "source": "HGNC:7782",
      "target": "HGNC:1516",
      "type": "REGULATES",
      "properties": {
        "direction": "activation",
        "source": "wikipathways_get_pathway_components(WP:WP408)"
      }
    },
    {
      "source": "HGNC:7782",
      "target": "HGNC:4553",
      "type": "REGULATES",
      "properties": {
        "direction": "activation",
        "source": "wikipathways_get_pathway_components(WP:WP408)"
      }
    },
    {
      "source": "HGNC:1548",
      "target": "CHEMBL:53463",
      "type": "METABOLIZES",
      "properties": {
        "product": "doxorubicinol (cardiotoxic metabolite)",
        "context": "CBR1 converts doxorubicin to doxorubicinol, which accumulates in cardiac tissue",
        "source": "hgnc_get_gene(HGNC:1548)"
      }
    },
    {
      "source": "HGNC:1549",
      "target": "CHEMBL:53463",
      "type": "METABOLIZES",
      "properties": {
        "product": "doxorubicinol (cardiotoxic metabolite)",
        "context": "CBR3 genetic variants affect doxorubicin metabolism rate",
        "source": "hgnc_get_gene(HGNC:1549)"
      }
    },
    {
      "source": "HGNC:40",
      "target": "CHEMBL:53463",
      "type": "TRANSPORTS",
      "properties": {
        "mechanism": "ATP-dependent drug efflux",
        "context": "P-glycoprotein pumps doxorubicin out of cells; dual role in toxicity (protects normal tissue) and resistance (reduces efficacy in tumors)",
        "source": "hgnc_get_gene(HGNC:40)"
      }
    },
    {
      "source": "HGNC:7765",
      "target": "WP:WP2735",
      "type": "MEMBER_OF",
      "properties": { "source": "wikipathways_get_pathways_for_gene(NF1)" }
    },
    {
      "source": "HGNC:7765",
      "target": "WP:WP4223",
      "type": "MEMBER_OF",
      "properties": { "source": "wikipathways_get_pathways_for_gene(NF1)" }
    },
    {
      "source": "HGNC:7782",
      "target": "WP:WP408",
      "type": "MEMBER_OF",
      "properties": { "source": "wikipathways_get_pathways_for_gene(NFE2L2)" }
    },
    {
      "source": "HGNC:7782",
      "target": "WP:WP2884",
      "type": "MEMBER_OF",
      "properties": { "source": "wikipathways_get_pathways_for_gene(NFE2L2)" }
    },
    {
      "source": "HGNC:7782",
      "target": "WP:WP4357",
      "type": "MEMBER_OF",
      "properties": { "source": "wikipathways_get_pathways_for_gene(NFE2L2)" }
    },
    {
      "source": "HGNC:11180",
      "target": "WP:WP408",
      "type": "MEMBER_OF",
      "properties": { "source": "wikipathways_get_pathway_components(WP:WP408)" }
    },
    {
      "source": "HGNC:2874",
      "target": "WP:WP408",
      "type": "MEMBER_OF",
      "properties": { "source": "wikipathways_get_pathway_components(WP:WP408)" }
    },
    {
      "source": "HGNC:5013",
      "target": "WP:WP408",
      "type": "MEMBER_OF",
      "properties": { "source": "wikipathways_get_pathway_components(WP:WP408)" }
    },
    {
      "source": "HGNC:1516",
      "target": "WP:WP408",
      "type": "MEMBER_OF",
      "properties": { "source": "wikipathways_get_pathway_components(WP:WP408)" }
    },
    {
      "source": "HGNC:4553",
      "target": "WP:WP408",
      "type": "MEMBER_OF",
      "properties": { "source": "wikipathways_get_pathway_components(WP:WP408)" }
    },
    {
      "source": "CHEMBL:53463",
      "target": "NCT:00304083",
      "type": "TESTED_IN",
      "properties": {
        "context": "Doxorubicin-based chemotherapy for NF1-associated MPNSTs",
        "source": "clinicaltrials_get_trial(NCT:00304083)"
      }
    },
    {
      "source": "CHEMBL:1738",
      "target": "NCT:06220032",
      "type": "TESTED_IN",
      "properties": {
        "context": "Dexrazoxane for prevention of anthracycline-induced cardiac dysfunction",
        "source": "clinicaltrials_get_trial(NCT:06220032)"
      }
    }
  ]
}
